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Assessment of urinary mephenytoin metrics to phenotype for
CYP2C19 and CYP2B6 activity
Abstract
OBJECTIVES: (S)-Mephenytoin is selectively metabolised to (S)-4'-hydroxymephenytoin by
CYP2C19. The urinary excretion of 4'-hydroxymephenytoin reflects the activity of individual enzymes.
We evaluated fractioned urinary collection and beta-glucuronidase pre-treatment in order to determine
the optimal CYP2C19 metrics. We also assessed whether urinary excretion of N-desmethylmephenytoin
(nirvanol) might be a useful CYP2B6 metric in in vivo studies. METHODS: A 50-mg dose of
mephenytoin was administered to 52 volunteers as a component of phenotyping cocktails in four
separate studies. Urine was collected up to 166 h post-dose. Urinary excretion of
4'-hydroxymephenytoin and nirvanol was quantified by liquid chromatography-tandem mass
spectrometry, and common CYP2C19 and CYP2B6 genotypes were determined. RESULTS:
Cumulative excretion of 4'-hydroxymephenytoin in urine with beta-glucuronidase treatment collected
from before mephenytoin administration up to 12-16 h thereafter showed the greatest difference
between CYP2C19 genotypes and the lowest intra-individual variability (7%). Renal elimination of
nirvanol was highest for a *4/*4 individual and lowest for individuals carrying the *5/*5 and *1/*7
genotype, but lasted for several weeks, thus making its use in cross-over studies difficult.
CONCLUSION: Cumulative urinary excretion of 4'-hydroxymephenytoin 0-12 h post-administration is
a sensitive and reproducible metric of CYP2C19 activity, enabling the effect of a drug on CYP2C19 to
be assessed in a small sample size of n=6 volunteers. While nirvanol excretion may reflect CYP2B6
activity in vivo, it is not useful for CYP2B6 phenotyping.
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ABSTRACT 
 
Objectives: (S)-Mephenytoin is selectively metabolised to (S)-4’-hydroxymephenytoin by 
CYP2C19. Urinary excretion of 4’-hydroxymephenytoin reflects individual enzyme activity. 
We evaluated fractioned urinary collection and β-glucuronidase pre-treatment to assess the 
optimal CYP2C19 metric. Furthermore, we addressed whether urinary excretion of 
N-desmethylmephenytoin (nirvanol) might be a useful CYP2B6 metric in vivo. 
Methods: 50 mg of mephenytoin was administered to 52 volunteers as part of phenotyping 
cocktails in four separate studies. Urine was collected up to 166 hours postdose. Urinary 
excretion of 4’-hydroxymephenytoin and nirvanol was quantified by LC-MS/MS, and 
common CYP2C19 and CYP2B6 genotypes were determined. 
Results: Cumulative excretion of 4’-hydroxymephenytoin in urine with β-glucuronidase 
treatment collected from before mephenytoin administration up to 12-16 hours thereafter 
showed the greatest difference between CYP2C19 genotypes and the lowest intraindividual 
variability (7 %). Renal elimination of nirvanol was highest for a *4/*4 individual and lowest 
for individuals carrying the *5/*5 and *1/*7 genotype, but lasted for several weeks, thus 
making its use in cross-over studies difficult. 
Conclusion: Cumulative urinary excretion of 4’-hydroxymephenytoin 0-12 hours is a 
sensitive and reproducible metric of CYP2C19 activity, allowing a small sample size of n=6 
volunteers to assess the effect of a drug on CYP2C19. While nirvanol excretion may reflect 
CYP2B6 activity in vivo, it is not useful for CYP2B6 phenotyping. 
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INTRODUCTION 
The genetically polymorphic human cytochrome P450 enzyme CYP2C19 is involved in the 
metabolism of several frequently prescribed drugs like omeprazole1 and diazepam2. 
While CYP2C19*1 represents the wild type allele, 26 variant alleles have been described to 
date.3 There are pronounced differences in the frequency of polymorphisms between ethnic 
groups. The CYP2C19 alleles *24 and *35 which are almost exclusively responsible for 
truncated CYP2C19 proteins with absent functional activity are present in 30% and 5% of the 
Asian, 17% and 0.4% of the African-American, and 15% and 0.04% of the Caucasian 
population, respectively. The remaining defective alleles are rarely encountered throughout all 
ethnicities.6 
Fast and reliable genotyping assays have been developed, enabling a clear assignment to the 
poor or extensive metabolizer phenotype.7 Individual enzyme activity, however, is also 
influenced by various non-genetic factors like the intake of drugs that inhibit or induce 
CYP2C19, age or different disease states.8, 9 In contrast to a genetic approach, phenotyping 
determines actual enzyme activity in vivo, and thus can take these factors into account and 
quantify their effects. Hence, there is an essential demand for reliable, selective, and 
reproducible CYP2C19 phenotyping metrics. 
Mephenytoin is the standard probe drug for the assessment of CYP2C19 activity in humans10 
and has successfully been employed in several cocktail phenotyping studies to evaluate the 
effects of drugs or disease states on CYP2C19 activity in vivo.11, 12 Omeprazole and proguanil 
are used as alternative probe drugs for CYP2C19 phenotyping. But, in addition to CYP2C19 
mediated hydroxylation, CYP3A4 mediated sulfoxidation of both omeprazole and 5-
hydroxyomeprazole, the metabolite formed by CYP2C19, occurs.1 Interactions with CYP3A4 
(phenotyping) substrates and or CYP3A4 inhibitors could be the consequence when applied 
concomitantly, which may be one reason why CYP3A4 substrates were not administered 
simultaneously with omeprazole in published phenotyping cocktails.13, 14 Additionally, due to 
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the short half-life of omeprazole, plasma sampling has to take place early after administration 
and results may therefore be influenced by dissolution or enteral absorption of the probe drug. 
The within-subject variability of omeprazole metrics thus is substantial (35~40%)15 and could 
not be attributed to variation in CYP2C19 activity only. Hence, omeprazole does not appear 
to be an optimal alternative CYP2C19 probe. Proguanil metabolism seems to be affected 
significantly by CYP3A4 and is not recommended for CYP2C19 phenotyping anymore.10  
Mephenytoin is administered as a racemic mixture and undergoes a complex metabolism (see 
Figure I). Only extensive metabolizers (EM), expressing functional CYP2C19, are able to 
hydroxylate (S)-mephenytoin to (S)-4´-hydroxymephenytoin, which is subsequently 
conjugated almost completely to the (S)-4´-hydroxymephenytoin glucuronide and excreted 
renally.16, 17 In CYP2C19 deficient poor metabolizers (PM), (S)-mephenytoin is 
biotransformed via slow N-demethylation, which in vitro is preferentially mediated by 
CYP2B6 (with minor contribution of CYP2C9), resulting in the formation of (S)-nirvanol.18-20 
(R)-mephenytoin is preferably demethylated to (R)-nirvanol and hydroxylated only to a small 
extent.16  
Based on this highly stereoselective metabolism, either the enantiomeric S/R ratio of 
unchanged mephenytoin in 0-8 hour urine21 or the amount of 4´-hydroxymephenytoin 
recovered in urine22 are used as CYP2C19 phenotyping metrics. Shortcomings of the S/R 
ratio have been reported.23, 24 Therefore we chose the molar urinary recovery of 4´-
hydroxymephenytoin for our investigations. 
The urinary recovery of 4´-hydroxymephenytoin was widely used to phenotype for CYP2C19 
activity during the last twenty years, but validation of this metric is incomplete in the 
literature. The optimal duration of urine collection remains to be defined. In addition, it is 
unknown whether cumulative or fractioned urine collections yield better results. Finally, it is 
unclear whether enzymatic hydrolysis of 4´-hydroxymephenytoin glucuronide prior to 
analysis is inevitable, or whether the small fraction of free 4´-hydroxymephenytoin found in 
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untreated urine satisfactorily reflects individual CYP2C19 enzyme activity when a sensitive 
LC-MS/MS assay is used.  
An increasing number of compounds, e.g. bupropion, cyclophosphamide or efavirenz, have 
been identified as substrates of the highly polymorphic enzyme CYP2B625,26. As (S)-
mephenytoin demethylation to (S)-nirvanol is mediated mainly by CYP2B6 in vitro, it is 
tempting to use mephenytoin as a dual phenotyping drug for CYP2C19 and CYP2B6. 
However, it is unknown whether urinary excretion of nirvanol represents an appropriate 
metric for CYP2B6 in vivo.20 
The objective of our present work was to identify the optimal CYP2C19 phenotyping metric 
of urinary 4´-hydroxymephenytoin excretion. To decrease the risk of sedation particularly in 
poor metabolizers,27 we further examined the feasibility of phenotyping with 50 mg of 
mephenytoin in a Caucasian population. Additionally, we wanted to explore whether 
phenotyping of CYP2B6 can be accomplished with mephenytoin in vivo. 
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METHODS 
Volunteers and general procedures  
A total number of 52 male, healthy Caucasians participated in four phenotyping cocktail 
studies (A, B, C and D) which included mephenytoin as a CYP2C19 probe. Two of the 
volunteers took part in two studies; to avoid confounding, for these subjects only the data 
from the first study in which they participated was used for evaluation. The demographics of 
study participants is shown in Table I. 
All studies were approved by the Ethics Committee of the Medical Faculty of the University 
of Cologne, Germany, and were conducted in accordance with the laws of Germany. Written 
informed consent was obtained from each subject before participating in the studies. All 
subjects were in good health as indicated by pre- and post-study screening examinations. 
To rule out possible interactions with the cytochrome P450 system, all study participants were 
advised to avoid the consumption of food or beverages containing methylxanthines, grapefruit 
or alcohol from at least 48 hours prior to the drug administration until 48 hours thereafter. In 
case of study C and D the dietary restrictions were extended on beverages containing quinine 
and maintained until the end of the post study examinations. Therapeutic or illicit drug intake 
two weeks preceding the trials was an exclusion criteria. All subjects were regularly asked for 
the occurrence of adverse events, their well being was continuously surveyed, and blood 
pressure and pulse rate were recorded regularly. 
In all four studies the subjects had to empty their bladder completely before administration of 
the phenotyping cocktail. Half a tablet of Epilan Gerot (Gerot Pharmazeutika, Vienna, 
Austria), corresponding to 50 mg racemic mephenytoin, was administered to each study 
participant as part of a phenotyping cocktail for important drug-metabolizing enzymes and 
transporters. The individual dose was determined by weighing the tablet halfs. Food and fluid 
intake as well as body position (supine postion until 6 hours postdose) during the studies was 
standardized. 
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Individual study designs and objectives 
Study A was a one period, single dose cocktail phenotyping pilot study. Studies B, C and D 
were cocktail drug interaction studies in which the effect of an investigational drug in a Test 
period was compared to a Reference period. These three studies had a randomized, placebo-
controlled cross-over design. The phenotyping drugs used in each of the four studies are 
shown in Table II. 
Studies A and B were primarily used to assess β-glucuronidase pretreatment of the samples 
and fractioned vs. cumulative urine collection. The procedures of these studies has already 
been described in more detail.11, 28 
The primary phenotyping objectives of study C with regard to mephenytoin were the 
generation of confirmatory data for variability and selectivity evaluations of the CYP2C19 
metrics as well as a more thorough characterization of the slow nirvanol excretion. In this 
study, urine was collected in-house until 48 hours postdose and completed by two additional 
overnight in-house urine collection periods from 86-94 and 158-166 hours postdose. There 
was a washout phase of 4 weeks between both study periods. 
The objective of study D for this evaluation was further confirmation of intraindividual 
variability data with respect to CYP2C19 phenotpying. In this study, a washout phase of 2 
weeks was used between study periods. 
 
Urine and blood sampling 
In all studies urine was collected in 2 L plastic containers. The containers were cooled at 
+4°C during the collection. Exact duration of urine collection (for scheduled periods in the 
individual studies see Table I) and the pH value were recorded for each sample. The volume 
of urine was determined by weighing the containers assuming a mean density of 1 g/mL for 
urine. Aliquots of 10 mL were stored in plastic tubes at –80°C until analysis.  
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Whole blood samples for genotyping were drawn into tubes containing ethylene diamine 
tetraacetic acid (EDTA tubes, Sarstedt, Nümbrecht, Germany) before the first drug 
administration in all studies. 
 
Urine analysis by LC-MS/MS 
Mephenytoin, nirvanol and 4´-hydroxymephenytoin were analyzed by a validated assay for 
liquid chromatography tandem mass spectrometry as described earlier.29 Both the fraction of 
free, unconjugated 4´-hydroxymephenytoin and total 4´-hydroxymephenytoin after 
β−glucuronidase pre-treatment29 were measured in samples of study A and B. For study C and 
D only total 4´-hydroxymephenytoin concentrations up to 12 hours postdose were determined, 
while nirvanol concentrations were determined for all collection periods of study A, B and C. 
 
Genotyping  
Genotyping for CYP2C19 was performed for all subjects participating in studies A, B and C. 
DNA was extracted from blood samples using a standard phenol-chloroform extraction 
method. Analysis for allele CYP2C19*2 was performed by a polymerase chain reaction / 
restriction fragment length polymorphism method as described by de Morais et al..4 The 
volunteers of studies A, B and C were also genotyped for CYP2B6. Single nucleotide 
polymorphisms (SNPs) accounting for the CYP2B6 alleles *2, *3, *4, *6 and *7 were 
determined as described by Lang et al..30 
 9
Data Analysis 
Calculation of urinary recovery. For each cumulative and each fractioned collection period, 
the urinary recovery of metabolites was calculated as the molar excretion of 4´-
hydroxymephenytoin or nirvanol in urine expressed as a percentage of the accurate dose of 
mephenytoin administered. Recovery for cumulative collection periods was calculated by 
summing up the results of the fractioned collection periods. Urinary excretion rates were 
calculated as molar excretion divided by sampling time.  
To estimate the amount of nirvanol excreted during periods without urine collection, the 
following formula was used in study C:  
)21(21)21( ttRRAe −⋅⋅=−  
In this formula, Ae reflects the amount excreted, R is the mean excretion rate in the collection 
interval before and after the period in which no urine was collected, respectively, and t is the 
corresponding time where the adjacent collection intervals ended or started. 
CYP2C19 genotype and 4´-hydroxymephenytoin metrics. To identify the CYP2C19 metric 
which reflects the CYP2C19 genotype best, urinary recovery of 4´-hydroxymephenytoin [%] 
was calculated for fractioned and cumulative collection intervals of the respective Reference 
periods, each with and without previous deconjugation of glucuronic acid, in studies A, B and 
C. Kruskal-Wallis one way analysis of variance (ANOVA) with CYP2C19 genotype as the 
independent parameter and the various metrics as dependent parameters was used for 
statistical analysis. 
CYP2B6 genotype and nirvanol metrics. For a comparison of nirvanol excretion between 
CYP2B6 genotypes, fractioned and cumulative urinary recovery of nirvanol [%] was 
calculated for study A, for the respective first study periods of Study B (assuming that 
propiverine, the drug characterized in this interaction study, had no effect on nirvanol 
excretion) and for the respective Reference periods of study C. For nirvanol metrics in study 
B, it was not possible to use the Reference period only because after two weeks of wash-out, 
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in the second period there was still a pronounced excretion of nirvanol prior to administration 
of the mephenytoin test dose. Comparison of nirvanol excretion to CYP2B6 genotype is 
descriptive only. 
Intra-subject variability of CYP2C19 and CYP2B6 metrics. To determine the intra-subject 
variability of 4´-hydroxymephentoin and nirvanol excretion parameters, respectively, the 
intraindividual coefficients of variation were calculated after logarithmic transformation of 
urinary recovery data from the residual variance obtained by the standard ANOVA approach 
used for bioavailability assessment (software BIAV, Stephan Rietbrock, 1994). For 4´-
hydroxymephentoin metrics, data from both Test and Reference periods of the studies B, C, 
and D were used, and all calculations were performed for fractioned and cumulative 
collection periods, each with and without previous deconjugation of glucuronic acid. In the 
case of nirvanol metrics, intraindividual coefficients of variation for fractioned and 
cumulative excretion could only be calculated for study C because the wash-out period was 
too short in studies B and D. Based on the intraindividual coefficients of variation, the sample 
size needed for a cross-over drug interaction study with the CYP2C19 and CYP2B6 metrics 
identified was assessed assuming a power of 80%, a range of “no drug interaction“ from 0.8 
to 1.25 and a significance level of 5% by means of confidence intervals as described by 
Diletti et al..31 
All other analyses were performed with SPSS 12.00 (SPSS Inc., Chicago, IL, USA) and Excel 
2000 (Microsoft Corp., Redmond, WA, USA). For all statistical procedures P < .05 was 
considered significant. Results are given as arithmetic means ± standard deviations (SD) 
unless stated otherwise. 
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RESULTS 
In general, all phenotyping cocktails were well tolerated. No severe adverse effects related to 
mephenytoin were observed throughout all studies. Since analytical selectivity had been 
validated previously, no interfering peaks were observed in any of the chromatograms.  
4´-hydroxymephenytoin metrics for CYP2C19 activity. Analysis of CYP2C19 genotype for 
studies A, B, and C resulted in 24 homozygous CYP2C19*1/*1 carriers, 12 heterozygous 
CYP2C19*1/*2 extensive metabolizers and one poor CYP2C19*2/*2 metabolizer. (Volunteer 
B11, who was a carrier of the CYP2C19*1/*2 genotype, also took part in study C. Therefore, 
the results obtained for this subject in study C were excluded from further evaluation.) 
Respective numbers for individual studies A, B and C were 5, 5, 0; 12, 3, 1; and 7, 4, 0. The 
effect of CYP2C19 genotype on urinary excretion of 4´-hydroxymephenytoin was statistically 
significant for cumulative urine collections from the administration of mephenytoin to 6 or 
more hours postdose when combined with β-glucuronidase pre-treatment of the samples (see 
Table III). A significant genotype effect was also seen for fractioned collection of 
(deglucuronidated) urine from 2 to 8 hours (data available for studies A and B; n=26) with a 
p-value of 0.036. Apart from that, neither cumulative collection without previous 
deconjugation of glucuronic acid, nor all other fractioned urine sampling periods provided 
significant results (data not shown). The one CYP2C19*2/*2 homozygote poor metabolizer 
was, however, identified in all cumulative and fractioned collection intervals, because 
excretion of 4´-hydroxymephenytoin was roughly 100-fold lower than in carriers of at least 
one *1 allele. This is also indicated by comparison of urinary excretion rates as depicted in 
Figure II. Without deglucuronidation, 4´-hydroxymephenytoin concentrations were below the 
lower limit of quantification in all samples of the poor metabolizer, whereas all postdose 
concentrations were above the lower limit of quantification in the group of extensive 
metabolizers. 
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In the drug-drug interaction studies where we used the residual error to estimate 
intraindividual variability (studies B, C, D), there was no relevant effect of the potentially 
interacting drugs on CYP2C19 metrics (data not shown). As it becomes evident from Figure 
III, the lowest intraindividual variability of 4´-hydroxymephenytoin recovery was achieved by 
cumulative collection periods combined with β-glucuronidase pre-treatment. Because of the 
findings on deglucuronidation in studies A and B, only β-glucuronidase pretreated samples 
were analysed for studies C and D. Overall intra-subject variability from these samples was 
67%, 57%, 22%, 11% and 7% for urine collection periods 0-2 hours (study included: B), 0-4 
hours (B/D), 0-6 hours (B/D), 0-8 hours (B/C) and 0-12 hours (B/C/D) after oral 
administration of 50 mg mephenytoin, respectively. As expected, for the longer sampling 
periods these values were clearly lower than intersubject variation (CV 72%, 45%, 32%, 25% 
and 23% for the respective sampling periods). Further extension of collection periods up to 0-
16 hours (B) or 0-24 hours (B) hours postdose led to coefficients of variation of 6 % and 11%, 
respectively, and thus did not provide clearly better results. On the basis of these values for 
intraindividual variability, sample sizes of 24, 8, or 6 subjects were calculated for cross-over 
studies to assess an effect on CYP2C19 phenotype, if collection periods of 0 to 6 hours, 0 to 8 
hours, or 0-12 or more hours postdose, respectively, are used. 
Nirvanol metrics for CYP2B6 activity. Nirvanol excretion was very slow, with elimination 
rates being almost unchanged during the first week after mephenytoin administration. Even 
after the 4 weeks wash-out period in study C, concentrations above the lower limit of 
quantification (30 ng/ml) were found in 7 of 12 samples. Mean ± SD urinary excretion of 
nirvanol within 166 hours after cocktail administration in the reference periods of study C was 
3.2 ± 1.4 mg and thus reached 6.4 ± 2.7% of molar mephenytion dose. 
Excretion of nirvanol depending on the CYP2B6 genotype in studies A, B and C is shown 
in Figure IV. In this three studies, the following CYP2B6 genotypes were determined: *1/*1, 
n=10; *1/*2, n=2; *4/*4, n=1; *1/*5, n=6 (Subject B11 excluded from further evaluation, thus 
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*1/*5, n=5); *5/*5, n=2; *1/*6, n=8; *6/*6, n=3 and *1/*7, n=2. For these genotypes mean 
urinary excretion up to 24 hours postdose was 0.72–, 1.94-, 1.07-, 0.63-, 0.82-, 1.64-, and 
0.63-fold compared to homozygote carriers of the wild type allele. Four volunteers could not 
be assigned clearly to one of the genotypes examined.  
For studies B and D, a wash out phase of 2 weeks between both study periods resulted in a 
considerable carry-over of nirvanol into the second period; therefore, intraindividual 
variability of nirvanol excretion could only be calculated for study C. Figure VI shows that 
intraindividual variability for cumulative urine collections declined with increasing collection 
time reaching 27%, 23%, 22%, 22% and 19% for collection periods from mephenytoin 
administration up to 24 hours, 36 hours, 48 hours, 94 hours and 166 hours thereafter. On the 
basis of these intraindividual coefficients of variation, sample sizes of 28, 24, 24, 20 or 14 
individuals were calculated to be required for cross-over studies to assess the effect of 
CYP2B6 phenotype, if collection periods of 0-24, 0-36, 0-48, 0-94 or up to 166 hours, 
respectively, are used.  
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DISCUSSION 
Our results indicate that the quantification of 4´-hydroxymephenytoin with previous 
deglucuronidation of samples in a cumulated urine collection 0-12 h after administration of 50 
mg mephenytoin is the most suitable mephenytoin-based phenotyping metric for CYP2C19. 
Under these conditions, an intraindividual coefficient of variation as low as 7% and a 
significant relationship between CYP2C19 genotype and phenotyping metric was seen. A 
small sample size of n=6 would be sufficient to assess a potential inhibitory or inductive 
effect of a drug on CYP2C19 activity, if this phenotyping metric is used in a crossover study. 
In contrast, mephenytoin was not useful to assess CYP2B6 activity in vivo. 
4´-hydroxymephenytoin metrics for CYP2C19 activity. Characteristics of a probe drug for 
metabolic phenotyping should include good tolerability and availability, lack of drug-drug 
interaction with other probes as well as high sensitivity and reproducibility.32 The use of 
mephenytoin as a phenotyping probe for CYP2C19 activity in man meets most of these 
criteria. Among the advantages of mephenytoin, a high reproducibility between two or more 
study periods (Table IV), a significant gene-dose relationship,33, 34 and a validated lack of 
drug-drug interaction between mephenytoin and numerous other phenotyping probes, 
including the other components of the cocktails used here, have to be appreciated.35, 36, 37 
However, also a number of reservations have been expressed against mephenytoin. Severe 
sedation after administration of 100 mg mephenytoin has been reported in poor metabolizers 
and in subjects with low body mass index.27 Additionally, the urinary recovery of 4´-
hydroxymephenytoin is, as any urine-based metric, susceptible to incomplete or deficient 
urine collection.21 Finally, mephenytoin has lost its clinical relevance and is no longer 
commercially available in the United States and most European countries. Nevertheless, for 
CYP2C19 phenotyping purposes, if available mephenytoin seems to date to be the best 
choice. 
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In comparison to the S/R ratio the application of the urinary recovery of 4´-
hydroxymephenytoin appears to be favorable as the reliability of the S/R ratio is 
compromised by the presence of a pH and storage labile (S)-mephenytoin cysteine conjugate 
which leads to an increased risk of false phenotype classification by 1.5%.23, 24, 38; such 
problems do not occur with 4’-OH-mephenytoin29.  
However, no systematic efforts concerning the optimization of 4´-hydroxymephenytoin 
recovery in urine as a CYP2C19 metric have been reported since this metric was introduced 
more than twenty years ago.22 Only few studies with urinary collection intervals deviating 
from the “traditional” 8 hours were conducted.33, 39 Therefore, we tested various urinary 
collection periods of different duration to assess an optimal collection interval.  
To facilitate the analytical sample processing method we firstly examined whether the small 
fraction of free 4´-hydroxymephenytoin present in untreated urine would satisfactorily reflect 
individual CYP2C19 activity. But, in spite of the applied sensitive LC-MS/MS assay our 
investigations clearly support the demand for the deglucuronidation of urine before analysis 
since the omission of β-glucuronidase pre-treatment resulted in an overall loss of 
reproducibility and of phenotype-genotype relationship. Hence, the well recognized intra- and 
interindividual variability of UDP-glucuronosyltransferase activity seems to be an important 
confounder.40 
Urinary recovery of 4´-hydroxymephenytoin allowed a clear identification of a poor 
metabolizer phenotype in all fractioned and cumulative collection periods. The quantification 
of 4’-hydroxymephenytoin in cumulated urine collections of at least 6 hours after dosing was 
statistically significantly affected by CYP2C19 genotype (table III). Regardless of this fact, 
the overlapping of the 95% confidence intervals (see Table III) for 4´-hydroxymephenytoin in 
homozygous and heterozygous extensive metabolizers indicate that no clear-cut 
differentiation between these genotypes can be made with this phenotyping metric. This 
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finding is in accordance with published results for 4´-hydroxymephenytoin urinary 
recovery.34  
Furthermore, our investigations demonstrate that optimal reproducibility is reached after 12 
hours of cumulative urine collection. A generally smaller susceptibility towards minor 
sampling errors in longer collection intervals as well as a minor interference of 4´-
hydroxymephenytoin excretion with mephenytoin absorption and distribution are likely 
reasons. In consequence, a lower sample size of n=6 is needed when urine is collected during 
12 h in comparison to a sample size of n=8 when the “traditional” 8 h sampling interval is 
chosen. There is remarkable concordance between literature data and our results (Table IV). 
Hence, an intraindividual coefficient of variation of below 10 % appears to be consistent for 
4´-hydroxymephenytoin urinary recovery for both the 100 mg and the 50 mg mephenytoin 
dose. 
 
We compared our results to published data on other established CYP2C19 metrics. In analogy 
to our results, a clear-cut discrimination between CYP2C19*1/*1 homozygote and *1/*2 
heterozygote extensive metabolizers was achieved neither with the S/R-Ratio of 
mephenytoin33, 41 nor with the omeprazole metabolic ratio.42, 43 Similar finding for several 
metrics indicate that although homozygous extensive metabolizers may have a slightly higher 
CYP2C19 activity than heterozygous extensive metabolizers, this difference is probably not 
relevant for any drug metabolized by CYP2C19. As presented in Table IV, urinary recovery 
of 4´-hydroxymephenytoin yields the lowest intraindividual coefficients of variation 
throughout all phenotyping metrics. This was not achieved by a generally low variability of 
this metric (as compared to metabolic ratios); indeed, intersubject variability remained 3-fold 
higher for the 0-12 hours sampling period. The principal reason for this superior performance 
seems to be caused by the analytical assay. Mass spectrometric quantification of 4´-
hydroxymephenytoin following deglucuronidation takes place at concentrations that are more 
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than 200 times above the lower limit of quantification. In contrast, many of the samples used 
for the determination of omeprazole metabolic ratio and the S/R ratio of mephenytoin, 
respectively, exhibit concentrations close to or below the lower limit of quantification of the 
HPLC-based analytical method used in the respective studies.  
In conclusion, we propose to carry out CYP2C19 phenotyping with a low dose of 50 mg 
mephenytoin and cumulative urinary collection of 12 hours , instead of 8 hours, combined 
with previous deglucuronidation and LC-MS/MS detection of 4´-hydroxymephenytoin. 
 
Nirvanol metrics for CYP2B6 activity. Although (S)-nirvanol formation from (S-
mephenytoin) has been proved by in vitro studies,18, 19, 30 respective parameters are not 
established as an in vivo phenotyping metrics. Currently, in the only study available, the 
autoinduction by artemisinin has tentatively been assessed using the (S)-nirvanol to (S)-
mephenytoin ratio.45 In the present study, we carried out only a limited evaluation of the 
suitability of nirvanol metrics to estimate CYP2B6 activity. Because of the diversity of the 
CYP2B6 gene, much higher sample sizes would be required to assess effects of CYP2B6 
genotypes on nirvanol excretion. With this limitation, indeed the high urinary excretion of 
nirvanol of the single homozygous carrier of the CYP2B6*4 allele is in accordance with 
previous findings for CYP2B6 mediated bupropion hydroxylation.46, and the low excretion 
rates for carriers of the *5 or *7 allele correspond to in vitro findings .30 However, the relative 
high nirvanol excretion of homozygote carriers of the *6 allele does not reflect previous 
findings in vivo. For those subjects a lower CYP2B6 mediated clearance of efavirenz and 
methadone was reported.47, 48 
Nevertheless, our investigations clearly show that mephenytoin is not optimal to phenotype 
for CYP2B6 activity, at least for cross-over studies. First of all, adequate intraindividual 
variability with coefficients of variation of 23 % resulting in a samples size of 24 subjects 
were achieved not earlier than 36 hours after cocktail administration. While cumulative 
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urinary collection of 36 hours is still feasible, a wash-out phase of more than six weeks 
between two consecutive study periods seems necessary to rule out carry-over of nirvanol. 
Phenotyping under such premises is not practicable. Besides, in addition to CYP2B6 as low 
affinity/high capacity component of (S)-mephenytoin demethylation the influence of CYP2C9 
as high affinity/low capacity component cannot be dismissed especially at low plasma 
concentrations that occur after a single phenotyping dosage.20 For this reasons, it seems more 
reasonable to validate other metrics such as buproprion hydroxylation as a phenotyping tool 
for CYP2B6 in vivo as it has been proposed.25 
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LEGEND OF FIGURES 
 
Figure I:  Supposed stereoselective metabolism of mephenytoin (MEP) to nirvanol (NIR) 
and 4´-hydroxymephenytoin (4OHM). Phase I enzymes mediating the metabolism of (S)-
mephenytoin are indicated; those for (R)-mephenytoin are unknown in vivo.16-20 
 
Figure II:  Mean urinary excretion rates of 4´-hydroxymephenytoin for different genotype 
groups after deglucuronidation in the reference periods of studies A, B and C. Note the 
different scaling on the second ordinate for the homozygous carrier of the CYP2C19*2 allele.  
 
Figure III:  Study B (n=16). Intraindividual variability of 4´-hydroxymephenytoin urinary 
recovery for fractioned and cumulative collection of urine, with and without previous β-
glucuronidase pre-treatment 
 
Figure IV:  Arithmetic means of cumulative urinary nirvanol recovery by carriers of 
different CYP2B6 genotypes in studies A, B and C (n=37, * Subject B11 excluded from 
further evaluation, thus *1/*5, n=5). For study B, only the results of the first period are shown 
irrespective of coadministration with the test drug in this interaction study. For study C, only 
results of the reference period are shown (for detailed explanation, see Methods section). 
Legend: Genotypes arranged by descending mean urinary recovery. 
 
Figure V:  Intraindividual variability of nirvanol urinary recovery for fractioned and 
cumulative collection of urine in study C (n=12). Data points at midpoint sampling time of 
each collection period; duration of collection periods indicated in the lower part of the figure. 
The figure includes extrapolated collection intervals 48 - 86 hours and 94 - 158 hour postdose.
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TABLES 
Table I. Demographic characteristic and urinary collection periods of all studies 
Study Number of subjects 
Age* 
(years) Height* [cm] 
Body weight* 
[kg] Urinary collection periods [h] 
A 10 31 (25-40) 185 (177-199) 85 (74-98) Predose, 0-2, 2-4, 4-6, 6-8, 8-12, 12-24 
B 16 29 (23-42) 182 (171-195) 78 (71-101) Predose, 0-2, 2-4, 4-6, 6-8, 8-12, 12-16, 16-24 
C 12 (11)** 36 (24-49) 181 (172-198) 80 (60-103) Predose, 0-4, 4-8, 8-12, 12-16, 16-24, 24-36, 
36-48, 86-94, 158-166 
D 16 (15)** 29 (21-43) 182 (173-194) 80 (66-99) Predose, 0-6, 6-12 
Total 54 (52)** 31 (21-49) 182 (171-199) 81(60-103) - 
* Mean values (range) of pre-study examinations 
** Only 52 different subjects took part in all studies. Subjects B09 and B11 are identical with subjects D16 and C10, 
respectively. 
 24
Table II. Other phenotyping drugs coadministered with mephenytoin in studies A to D 
Phenotyping drug Study A Study B Study C Study D 
amoxicillin 100 mg - - - 
caffeine 150 mg 150 mg 150 mg 150 mg 
chlorzoxazone 250 mg - - - 
dextromethorphan 30 mg 30 mg 30 mg 30 mg 
digoxin 0.5 mg - 0.5 mg - 
midazolam p.o. 2 mg* 2 mg** 2 mg** 2 mg** 
midazolam i.v. 1 mg* 1 mg** 1 mg** 1 mg** 
nicotine 0.5 mg - - - 
tolbutamide 125 mg 125 mg 125 mg 125 mg 
* Study A: 1 mg of midazolam i.v. with all other phenotyping drugs, followed by 2 mg of oral midazolam 90 minutes later 
** Study B, C and D: 2 mg of oral midazolam with all other phenotyping drugs, followed by 1 mg midazolam i.v. 240 
minutes later 
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Table III. Urinary recovery of 4´-hydroxymephenytoin relative to the mephenytoin dose for 
individual genotypes groups . Cumulative collection intervals were used, and samples were 
pretreated with β-glucuronidase.  
*1/*1 *1/*2 *2/*2 
Collection 
interval  Studies 
No. of 
subjects*  
urinary 
recovery 
[%] 95% CI 
urinary 
recovery 
[%] 95% CI 
urinary 
recovery 
[%] 95% CI p value
0-2 h A/B 26 (17/9/1) 3.1±2.1 2.1-4.2 2.6±2.0 0.9-4.2 0.02 - 0.199 
0-4 h A/B/C 37 (24/12/1) 14.1±5.7 11.7-16.5 12.9±5.0 9.7-16.1 0.06 - 0.189 
0-6 h A/B 26 (17/9/1) 20.6±3.8 18.7-22.6 17.1±3.4 14.3-20.0 0.10 - 0.029 
0-8 h A/B/C 37** (24/12/1) 26.3±3.8 24.7-27.9 23.3±4.6 20.4-26.2 0.15 - 0.040 
0-12 h A/B/C 37 (24/12/1) 29.7±3.7 28.2-31.3 26.9±4.2 24.2-29.6 0.24 - 0.048 
0-16 h B 16 (12/3/1) 31.8±3.0 29.9-33.7 25.6±2.6 19.2-32.0 0.32 - 0.025 
0-24 h A/B 26 (12/3/1) 31.9±3.7 30.0-33.9 27.9±3.3 25.1-30.7 0.49 - 0.028 
* Numbers in brackets: Number of subjects subdivided into genotype groups (CYP2C19*1/*1 / CYP2C19*1/*2 / 
CYP2C19*2/*2) 
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Table IV. Intraindividual variability for different CYP2C19 phenotyping metrics  
author metric 
dose of 
probe 
drug [mg] 
number of 
subjects 
number of 
study 
periods 
intraindividual 
CV [%] calculation 
Christensen et al.13  OMEP-
MRa 
20 24 2 25 “coefficient of variation” 
Kim et al.49  OMEP-
MRb 
30g/40h 24 6 18.5 
6.3-51.3 “median CV%” and range 
Balian et al.50 OMEP-
MRb 
20 5 3 5.8-64.3 “range of variability after 
repeated determinations” 
Yin et al.42 OMEP-
MRc 
40 27 3 18.2 
4.5-37.7 
“mean coefficient of 
variation” and range 
Tamminga et al.51 S/Rd 100 129 2 28 “mean of all individual 
coefficients of variation” 
Frye et al.36 4OHM 
recoverye 
100 14 3 7.4 “median within-subject 
coefficient of variation” 
Zhu et al.35 4OHM 
recoverye 
100 14 4 10.3 “median within-subject 
coefficient of variation” 
This study 4OHM 
recoveryf 
50 40 (27) 2 7 (11) intra-subject variability 
calculated by ANOVA for 
log-transformed urinary 
recovery data  
OMEP MR = omeprazole metabolic ratio, S/R = mephenytoin S/R ratio, 4OHM = urinary recovery of 4´-
hydroxymephenytoin  
a: calculated as plasma ratio omeprazole/5´-hydroxyomeprazole 3 hours postdose 
b: calculated as plasma ratio omeprazole/5´-hydroxyomeprazole 2 hours postdose 
c: calculated as plasma ratio AUC(omeprazole)/AUC(5´-hydroxyomeprazole) up to 12 hours postdose 
d: calculated as concentration ratio (S)-mephenytoin/(R)-mephenytoin in 8h urine 
e: calculated as total urinary recovery of 4´-hydroxymephenytoin in 8h urine 
f: calculated as molar urinary recovery of 4´-hydroxymephenytoin in 12h urine (data for 8 hour collection period in brackets) 
g: body weight 45-66 kg: 
h: body weight 67-90 kg 
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FIGURES 
 
 
 
 
 
 
 
 
Figure I:  Supposed stereoselective metabolism of mephenytoin (MEP) to nirvanol (NIR) 
and 4´-hydroxymephenytoin (4OHM). Phase I enzymes mediating the metabolism of (S)-
mephenytoin are indicated; those for (R)-mephenytoin are unknown in vivo.16-20 
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Figure II:  Mean urinary excretion rates of 4´-hydroxymephenytoin for different genotype 
groups after deglucuronidation in the reference periods of studies A, B and C. Note the 
different scaling on the second ordinate for the homozygous carrier of the CYP2C19*2 allele.  
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Figure III:  Study B (n=16). Intraindividual variability of 4´-hydroxymephenytoin urinary 
recovery for fractioned and cumulative collection of urine, with and without previous β-
glucuronidase pre-treatment 
 30
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
m
ol
ar
 u
rin
ar
y  
re
co
v e
ry
 [%
]
0 6 12 18 24
time after administration of 50 mg mephenytoin [h]
CYP2B6*4/*4, n=1
CYP2B6*6/*6, n=3
CYP2B6*1/*5, n=5*
CYP2B6*1/*1, n=10
CYP2B6*1/*6, n=8
CYP2B6*1/*2, n=2
CYP2B6*5/*5, n=2
CYP2B6*1/*7, n=2
 
 
Figure IV:  Arithmetic means of cumulative urinary nirvanol recovery by carriers of 
different CYP2B6 genotypes in studies A, B and C (n=37, * Subject B11 excluded from 
further evaluation, thus *1/*5, n=5). For study B, only the results of the first period are shown 
irrespective of coadministration with the test drug in this interaction study. For study C, only 
results of the reference period are shown (for detailed explanation, see Methods section).  
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Figure V:  Intraindividual variability of nirvanol urinary recovery for fractioned and 
cumulative collection of urine in study C (n=12). Data points at midpoint sampling time of 
each collection period; duration of collection periods indicated in the lower part of the figure. 
The figure includes extrapolated collection intervals 48 - 86 hours and 94 - 158 hour postdose. 
 
